181 related articles for article (PubMed ID: 26866983)
1. Pegylated Polyaspartamide-Polylactide-Based Nanoparticles Penetrating Cystic Fibrosis Artificial Mucus.
Craparo EF; Porsio B; Sardo C; Giammona G; Cavallaro G
Biomacromolecules; 2016 Mar; 17(3):767-77. PubMed ID: 26866983
[TBL] [Abstract][Full Text] [Related]
2. Mucus and Cell-Penetrating Nanoparticles Embedded in Nano-into-Micro Formulations for Pulmonary Delivery of Ivacaftor in Patients with Cystic Fibrosis.
Porsio B; Craparo EF; Mauro N; Giammona G; Cavallaro G
ACS Appl Mater Interfaces; 2018 Jan; 10(1):165-181. PubMed ID: 29235345
[TBL] [Abstract][Full Text] [Related]
3. Polyaspartamide-Polylactide Graft Copolymers with Tunable Properties for the Realization of Fluorescent Nanoparticles for Imaging.
Craparo EF; Porsio B; Mauro N; Giammona G; Cavallaro G
Macromol Rapid Commun; 2015 Aug; 36(15):1409-15. PubMed ID: 26010226
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
Günday Türeli N; Torge A; Juntke J; Schwarz BC; Schneider-Daum N; Türeli AE; Lehr CM; Schneider M
Eur J Pharm Biopharm; 2017 Aug; 117():363-371. PubMed ID: 28476373
[TBL] [Abstract][Full Text] [Related]
5. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(D, L-lactide) (PLA) based nanoparticles.
Essa S; Rabanel JM; Hildgen P
Eur J Pharm Biopharm; 2010 Jun; 75(2):96-106. PubMed ID: 20211727
[TBL] [Abstract][Full Text] [Related]
6. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo.
Xu Q; Ensign LM; Boylan NJ; Schön A; Gong X; Yang JC; Lamb NW; Cai S; Yu T; Freire E; Hanes J
ACS Nano; 2015 Sep; 9(9):9217-27. PubMed ID: 26301576
[TBL] [Abstract][Full Text] [Related]
7. Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier.
Di Gioia S; Trapani A; Castellani S; Carbone A; Belgiovine G; Craparo EF; Puglisi G; Cavallaro G; Trapani G; Conese M
Pulm Pharmacol Ther; 2015 Oct; 34():8-24. PubMed ID: 26192479
[TBL] [Abstract][Full Text] [Related]
8. PEGylation for enhancing nanoparticle diffusion in mucus.
Huckaby JT; Lai SK
Adv Drug Deliv Rev; 2018 Jan; 124():125-139. PubMed ID: 28882703
[TBL] [Abstract][Full Text] [Related]
9. Beyond PEGylation: Alternative surface-modification of nanoparticles with mucus-inert biomaterials.
Khutoryanskiy VV
Adv Drug Deliv Rev; 2018 Jan; 124():140-149. PubMed ID: 28736302
[TBL] [Abstract][Full Text] [Related]
10. Insulin loaded mucus permeating nanoparticles: Addressing the surface characteristics as feature to improve mucus permeation.
Pereira de Sousa I; Moser T; Steiner C; Fichtl B; Bernkop-Schnürch A
Int J Pharm; 2016 Mar; 500(1-2):236-44. PubMed ID: 26802494
[TBL] [Abstract][Full Text] [Related]
11. PEGylated Nanoparticles based on a polyaspartamide. preparation, physico-chemical characterization, and intracellular uptake.
Craparo EF; Cavallaro G; Bondì ML; Mandracchia D; Giammona G
Biomacromolecules; 2006 Nov; 7(11):3083-92. PubMed ID: 17096535
[TBL] [Abstract][Full Text] [Related]
12. Investigation of polymer and nanoparticle properties with nicotinic acid and p-aminobenzoic acid grafted on poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) via click chemistry.
Suksiriworapong J; Sripha K; Kreuter J; Junyaprasert VB
Bioconjug Chem; 2011 Apr; 22(4):582-94. PubMed ID: 21375231
[TBL] [Abstract][Full Text] [Related]
13. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy.
Osman G; Rodriguez J; Chan SY; Chisholm J; Duncan G; Kim N; Tatler AL; Shakesheff KM; Hanes J; Suk JS; Dixon JE
J Control Release; 2018 Sep; 285():35-45. PubMed ID: 30004000
[TBL] [Abstract][Full Text] [Related]
14. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.
Nafee N; Forier K; Braeckmans K; Schneider M
Eur J Pharm Biopharm; 2018 Mar; 124():125-137. PubMed ID: 29291931
[TBL] [Abstract][Full Text] [Related]
15. Margination of Fluorescent Polylactic Acid-Polyaspartamide based Nanoparticles in Microcapillaries In Vitro: the Effect of Hematocrit and Pressure.
Craparo EF; D'Apolito R; Giammona G; Cavallaro G; Tomaiuolo G
Molecules; 2017 Oct; 22(11):. PubMed ID: 29143777
[TBL] [Abstract][Full Text] [Related]
16. Regulating the surface poly(ethylene glycol) density of polymeric nanoparticles and evaluating its role in drug delivery in vivo.
Du XJ; Wang JL; Liu WW; Yang JX; Sun CY; Sun R; Li HJ; Shen S; Luo YL; Ye XD; Zhu YH; Yang XZ; Wang J
Biomaterials; 2015 Nov; 69():1-11. PubMed ID: 26275857
[TBL] [Abstract][Full Text] [Related]
17. Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus.
Xu Q; Boylan NJ; Cai S; Miao B; Patel H; Hanes J
J Control Release; 2013 Sep; 170(2):279-86. PubMed ID: 23751567
[TBL] [Abstract][Full Text] [Related]
18. Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?
Conte G; Costabile G; Baldassi D; Rondelli V; Bassi R; Colombo D; Linardos G; Fiscarelli EV; Sorrentino R; Miro A; Quaglia F; Brocca P; d'Angelo I; Merkel OM; Ungaro F
ACS Appl Mater Interfaces; 2022 Feb; 14(6):7565-7578. PubMed ID: 35107987
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol.
Yang M; Lai SK; Yu T; Wang YY; Happe C; Zhong W; Zhang M; Anonuevo A; Fridley C; Hung A; Fu J; Hanes J
J Control Release; 2014 Oct; 192():202-8. PubMed ID: 25090196
[TBL] [Abstract][Full Text] [Related]
20. Functionalized (poly(ɛ-caprolactone))₂-poly(ethylene glycol) nanoparticles with grafting nicotinic acid as drug carriers.
Suksiriworapong J; Sripha K; Kreuter J; Junyaprasert VB
Int J Pharm; 2012 Feb; 423(2):562-70. PubMed ID: 22155410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
